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In clinical practice, and in the medical literature, severe congenital malformations such as trisomy 18,
anencephaly, and renal agenesis are frequently referred to as ‘lethal’ or as ‘incompatible with life’.
However, there is no agreement about a deﬁnition of lethal malformations, nor which conditions should
be included in this category. Review of outcomes for malformations commonly designated ‘lethal’ reveals
that prolonged survival is possible, even if rare. This article analyses the concept of lethal malformations
and compares it to the problematic concept of ‘futility’. We recommend avoiding the term ‘lethal’ and
suggest that counseling should focus on salient prognostic features instead. For conditions with a high
chance of early death or profound impairment in survivors despite treatment, perinatal and neonatal
palliative care would be ethical. However, active obstetric and neonatal management, if desired, may also
sometimes be appropriate.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Antenatal screening, particularly the use of routine mid-
trimester ultrasound screening, has altered the diagnosis of major
congenital malformations. As a result, in many parts of the world it
is now uncommon for major malformations to be discovered at
birth [1]. Antenatal diagnosis potentially allows targeted diagnostic
testing, planning of delivery, counseling and education of couples,
and earlier postnatal intervention for newborns with congenital
malformations [2]. However, antenatal diagnosis may identify se-
vere abnormalities where treatment is unavailable, or unlikely to
be successful, and where fetal or neonatal death is a likely
outcome. Such cases are often referred to as ‘lethal malformation’
(LM) (Box 1).
The diagnosis of LM is often said to carry ethical and legal im-
plications for management during pregnancy, delivery, and post-
natally [3e6]. For example, it may permit obstetric management
focused on maternal well-being rather than on fetal survival,
termination of pregnancy (including late in pregnancy), or non-
resuscitation at birth [7]. But what do we mean when we refer tontre for Practical Ethics, Suite
Tel.: þ44 (0) 1865 286 888;
.ac.uk (D. Wilkinson).
r Ltd. This is an open access articlea malformation as ‘lethal’? Which conditions ﬁt into this category?
What are the ethical implications of diagnosis of LM?2. The concept of ‘lethal malformation’
The word ‘lethal’ is derived from the Latin ‘letalis’ (deadly), and
related to a Greek word meaning ‘oblivion,’ referring to the myth
that the souls of the dead forgot their lives on Earth after drinking
the waters of the River Lethe. Conventionally, ‘lethal’ is used to
describe something (e.g. an action or agent) that will cause death
[8].
In theory, there are several different ways to interpret the
description of a malformation as lethal (Box 2).
A review of the published literature on LM revealed no
consensus on which of these deﬁnitions should be applied [9]. The
ﬁrst deﬁnition does not apply to any of the commonly cited LMs,
and is not one found in the literature. The second deﬁnition is
probably the most plausible and the most frequently encountered
[5,10e13]. Chervenak and McCullough endorse this deﬁnition: ‘a
lethal condition, properly understood, invariably leads to death, i.e.,
there is no effective treatment that will prevent a condition, dis-
ease, or injury from causing death in the near future’ [14]. However,
this deﬁnition does not apply to any of the malformations that are
often described as lethal. Some papers have used the third deﬁni-
tion [15e18]. This raises a question about how high a chance ofunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Trisomy 13 or 18
Holoprosencephaly
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ranges from 50% to ‘almost all’ [16,19]. There is neither agreement
about the correct proportion, nor any obvious way to determine
where the cut-off should lie. The fourth deﬁnition is used in some
epidemiologic studies of neonatal mortality [20e22]. However, it
appears far too broad to correspond to the way that LM is used by
obstetricians and neonatologists.3. Which malformations are lethal?
Although Box 1 lists the most frequently cited LMs, more than
25 conditions are included in different lists [9]. No condition was
present on all lists, and there was considerable variation.
What is the outcome for these malformations? Table 1 presents
an attempt to estimate outcome; however, the values cited are
necessarily imprecise. High proportions of affected pregnancies are
terminated [47]. Since these conditions are associated with high
fetal death rate, survival rate also varies with the gestational age at
the time of diagnosis. Postnatal survival is also difﬁcult to estimate
because of selection bias in published cohorts, and because of the
problem of self-fulﬁlling prophecies [48,49]. Where a large pro-
portion of infants receive palliative care after birth, a highmortality
rate is inevitable [9].
What is clear from Table 1 is that survival of at least six months
has been described in all of the conditions frequently cited as le-
thal. Most strikingly, this includes both anencephaly and bilateral
renal agenesis. There has been a very recently published case
report of an infant in the USA with Potter syndrome who was
treated with antenatal amnio-infusion and neonatal renal dialysis
and who survived to be listed for renal transplantation at one year
of age.Box 2
Possible definitions of a ‘lethal congenital malformation’.
1. Fetal death: a condition that invariably leads to death in-
utero
2. Fetal death/neonatal death: a condition that invariably
leads to death either in utero or in the newborn period
regardless of treatment
3. Usual fetal/neonatal death: a condition that leads to death
in utero or in the newborn period in most cases
4. Associated with death: a condition that leads to fetal or
neonatal death in some cases4. The signiﬁcance of a ‘lethal diagnosis’: the examples of
trisomy 18 and 13
The severe autosomal trisomies, 18 (Edwards syndrome; T18)
and 13 (Patau syndrome; T13), are frequently described as lethal
[18,50e53]. Yet, recent population cohort studies show that more
than half of affected live-born infants survive for more than aweek,
and up to 20% survive for more than a year [18,29]. In a large US
series including 52,262 very low birth weight infants, 11% of infants
with T13 and 9% of infants with T18 survived to discharge [54]. It is
possible that even these values represent an underestimate of po-
tential survival rates, since in parts of the world where cardiac
surgery is offered to infants with T13 or T18, one-year survival rates
as high as 50% have been reported [55].
Why does it matter if these conditions are described as lethal?
The ﬁrst reason to be concerned about this terminology is its po-
tential for misunderstanding and miscommunication. We surveyed
more than 1000 obstetricians from the UK, Australia, and New
Zealand about the perinatal management of T18 [56]. The over-
whelming majority (85%) of obstetricians regarded T18 as a lethal
malformation. More than 50% regarded T18 as ‘incompatible with
life’. We did not ask obstetricians whether they would use these
terms in counseling, but a survey of parents from T13/T18 support
groups found that 93% had been told by health professionals that
their child's condition was ‘lethal or incompatible with life’ [57].
This contrasts with the evidence summarized above, and with
obstetricians' own understanding about survival. Three-quarters of
respondents estimated that at least 5% of affected infants would
survive for more than one year if treatment were provided [56].
Qualitative studies and narratives from parents of infants with
T13 or T18 describe feelings of anger and disillusionment and a
sense of being misled by health professionals as well as by the
language used [58e61]. Many parents reported that health care
providers were unable to look beyond adverse statistics [57].
Furthermore, the Internet has provided families with the ability to
do their own research and encounter alternate perspectives on
their child's condition. Within seconds of searching for ‘trisomy 18’
a parent may see pictures of many older children with trisomy 18,
smiling and happy, strong evidence against ‘incompatibility with
life’. If they have been told by their doctor that trisomy 18 is always
lethal, there may be repercussions for the family's ongoing capacity
to trust health professionals [44].
Another reason to be concerned about denoting a condition
such as T18 as ‘lethal’ is because of a worry that this language
contains concealed value judgments about the quality of life of
surviving infants [31,49]. Eighty percent of obstetricians in our
survey believed that T18 was not compatible with a ‘meaningful
life’ [56]. Labeling a condition as ‘lethal’ may also risk taking
decision-making from the parents [31,49]. In our survey, 23% of
obstetricians would never discuss or offer fetal monitoring in la-
bour for women after an antenatal diagnosis of T18, and 28% would
never offer caesarean section for fetal distress [56]. In the parent-
support group study, two-thirds of parents reported feeling pres-
sure to terminate their pregnancy [57].
There is a concept in medical ethics that shares some features
with that of LM: the concept of ‘medical futility’ [9,19]. Medical
futility emerged in the 1990s as a potential way to resolve disputes
between patients and doctors about life-sustaining treatment [62].
It reﬂected a perceived need by medical professionals to limit pa-
tient autonomy and to justify a decision not to provide treatment
that had been requested [62]. The basic idea was that although it
was important to respect patients' views about treatment, health
professionals were not obligated to provide futile treatment [63].
However, the concept of futility has fallen out of favour because of a
Table 1
Published outcome for severe congenital anomalies often described as lethal.a
Severe congenital anomalies Prevalence Probability of live birth
(in absence of termination)
Median postnatal
survival
Proportion surviving >1 week/>1 year Longest reported
survivals
Renal agenesis 1.7/10,000 [23] Not reported <24 h [23] <5% 13 months [97,98]
Anencephaly 10/10,000 pregnancies
2.6/10,000 births [24]
62e72% [25,26] <24 h [26,27]
55 min [28]
0e14%>1 week/7% >1 year [18,29] 10 months [30]
2.5 years [31]
Thanatophoric dysplasia 0.4/10,000 [32] Not reported Not reported Not reported 5 years [33]
9 years [34]
Trisomy 18 2.6/10,000 [24] 48e51% [35,36] 14 days [37] 35e65%>1 week/14e19% >1 year [18,29] 27 years [38]
30 years [39]
50 years [40]
Trisomy 13 1.2/10,000 [24] 28e46% [35,36] 10 days [37] 45e57%>1 week/14e21% >1 year [18,29] 19 year [41]
27 year [42]




a Using recent population cohort studies where available.
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[64,65].
First, there is a problemwith deﬁning futility. There have been at
least ﬁve different deﬁnitions proposed, and no agreement on
which should be used [64]. Some authors distinguish quantitative
from qualitative futility [63]. Treatment is quantitatively futile if it
has a very low chance of success. However, just as for the third
deﬁnition of LM, there is a problem with determining where the
statistical threshold should lie. Is a 90% chance of death high
enough, or should it be 95% or 99%? Trisomy 13/18 might appear
lethal on some deﬁnitions, but not others.
Second, even if a particular statistical threshold is used, there is
a problem with determining whether treatment would actually be
futile in an individual case. Even if treatment has not succeeded in
the past, there may have been technological changes that could
potentially improve survival. There may be speciﬁc features for an
individual patient that distinguish him from aggregated cohorts.
(For example, a fetus with T18 might have a structurally normal
heart and appear to have better prognosis, or might have hypo-
plastic left heart and have a much worse prognosis than average
[66].) Often there are limited data onwhich to base a prognosis. The
problem of self-fulﬁlling prophecies means that available data may
not be representative of actual chances of survival if treatment
were provided [48].
Third, the clearest and strictest available deﬁnition appears to
exclude almost all actual cases. Treatment is said to be ‘physio-
logically futile’ if there is no way for it to achieve its physiologic aim
[62]. For example, cardio-pulmonary resuscitation would be
physiologically futile if therewere literally no ability for it to restore
circulation and breathing. Analogously, a condition might be
denoted lethal (using the second deﬁnition) if survival is impossible
regardless of treatment. However, either of these deﬁnitions ap-
pears to render the concept relevant only in extremely rare cases,
and certainly not in T13 or T18.
Fourth, there is a concern that the term ‘futile’, particularly
when it is used qualitatively, amounts to ‘giving opinion disguised
as data’ [67]. Treatments are described as being ‘qualitatively futile’
when treatment might be able to sustain life but is not perceived to
amount to a beneﬁt for the patient. For example, providing inten-
sive care to a patient in a persistent vegetative state has been
described as being qualitatively futile [63]. Similarly, some deﬁni-
tions of LM include conditions associated with a persistent vege-
tative state or absent cognitive development [6,10,68,69]. In our
survey of obstetricians, 20% indicated that the best developmental
outcome in T18 is a vegetative state [56]. Yet, available data suggest
that children with T18 and T13, although usually profoundly
impaired, are not vegetative. Surviving children are reported to beaware of those around them, to hear and respond to sound, and to
learn and remember [39]. Most are unable to speak, yet are able to
communicate non-verbally at a basic level [70]. Whether this level
of function is sufﬁcient to outweigh the burdens of treatment
constitutes an important ethical question. It may or may not be in
the best interests of a child to provide particular treatment given
this prognosis [52,68,71]. However, it is clear that this involves a
judgment about the value of life in a severely impaired cognitive
state. Professional guidelines strongly endorse the idea that coun-
seling following prenatal diagnosis should be non-directive and
value neutral [72e74]. Whereas some authors have questioned
whether complete neutrality in counseling is possible or desirable
[72,75e77], there are good reasons for doctors to aspire to
neutrality inmost circumstances. One important way to do this is to
avoid language that contains implicit value judgments [78].
5. Beyond the concept of ‘lethal malformations’
We have criticized the concept of LM, but what does that mean
for counseling or for decision-making?
It might be possible to ﬁnd an alternative term to describe all of
the congenital conditions that are usually referred to as lethal. They
appear to share a high chance of death and profound impairment
regardless of attempted treatment. We could refer to ‘life-limiting’
conditions [79], ‘poor prognosis’ malformations, or ‘potentially le-
thal’ [79] malformations. However, any new term will have the
same problems of deﬁning the probability and severity of poor
outcome that would justify its application. Unless it is a term that
parents easily and reliably understand, it will need to be explained.
Instead, we have previously suggested that it would be better for
counseling to openly and honestly address the key prognostic
questions that parents are likely to ask after diagnosis of a severe
congenital malformation [9].
1. Diagnosis: what is the diagnosis, and how certain can practi-
tioners be?
2. Neonatal survival: what is the chance of survival past the
newborn period if treatments (including intensive life-
prolonging therapies) are provided?
3. Long-term survival: how long is the child likely to survive if life-
sustaining treatment is provided?
4. Long-term impairment and illness: if the newborn survives,
what long-term health problems and impairments are they
likely to experience? What is the range of possible outcomes?
5. Burden of treatment: what treatments would be required to
keep the newborn infant alive, and how burdensome would
these be for the child and the family?
Practice points
 Survival beyond the newborn period has been described
in all of the congenital malformations that are often
described as being ‘lethal’.
 The terms ‘lethal malformation’ or ‘incompatible with life’
should be avoided in counseling.
 A palliative approach to management during pregnancy,
delivery, and postnatally may be ethically appropriate for
fetuses with a very poor prognosis.
 An active approach to obstetric and neonatal care may
also be appropriate in these conditions to enable parents
to experience some time with their child while alive.
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be offered or provided to women and to fetuses and babies in the
setting of severe congenital malformations with a very high chance
of death or profound disability despite treatment. We have argued
that such malformations should not be called ‘lethal’. However, the
label should not change the treatment that is provided. The label
that we give to conditions is not ethically relevant to the options
that are appropriate. One additional advantage of avoiding the
‘lethal’ designationmay be that these conditions are not identical. If
we treat each condition (and indeed each child) on its merits, op-
tions may be appropriate in some circumstances and not in others.
Which options, then, should be provided to severe malforma-
tions such as those in Box 1? For all, the option of palliative care at
birth should be given to parents. The high chance of death or
profound impairment means that it is questionable whether
providing resuscitation and life-prolonging treatment is in the
child's best interests [80]. It is critical that high quality palliative
care is available to the infant and family [4,81]. It is important,
though, to ensure that parents and future parents are aware about
variable duration of survival. Provision of palliative care does not
necessarily mean that the child will die quickly [82]. Palliative
support does not need to be conﬁned to the postnatal period, and
there may be considerable beneﬁt to the family by offering a
palliative approach from the time of diagnosis, through to delivery,
and beyond [3,83,84]. There are perinatal palliative care programs
available in an increasing number of centres. A palliative (maternal-
focused) approach to obstetric care may mean that it is appropriate
to avoid monitoring in labour and to aim for vaginal delivery, if that
is consistent with a woman's wishes [6,85e87].
If palliative care is an option, what about the opposite? Should
resuscitation and intensive care be an option? Should fetal-
oriented obstetric management be available? Here a nuanced
answer is needed that takes into account the speciﬁcs of each case.
Nevertheless, we support the recommendation that an active
approach to obstetric management, including fetal monitoring,
cesarean section, and resuscitation, may be appropriate even in the
face of a high death rate [14,85,88,89]. Such treatment is not con-
trary to the interests of the child [89]. For some parents, the op-
portunity to experience some time with their child while s/he is
still alive may be extremely important [88]. On the other hand, this
does not mean that unlimited treatment should be made available
if requested by parents [90]. Invasive and intensive treatment,
particularly if prolonged, may not be in the interests of the child in
the face of very low chance of beneﬁt. Such treatment may also be
unreasonable in the setting of limited public health resources [62].
Health professionals may be justiﬁed in declining treatment in such
circumstances. However, such decisions must be made on the basis
of the child's speciﬁc circumstances, and on consistently and
transparently applied ethical principles rather than on the basis of a
label of ‘lethality’.
What about termination of pregnancy? The diagnosis of LM
would make no difference to decisions about termination in juris-
dictions that either do not permit termination on fetal grounds, or
alternatively that allow access to termination for a broad range of
fetal abnormalities. However, in some jurisdictions the diagnosis of
a ‘lethal’ malformation may permit termination of pregnancy, even
at a gestational age when this would otherwise be prohibited [91].
For example, the Texas Health and Safety Code [92] makes an
exception to the prohibition of pregnancy termination after 20
weeks if ‘the fetus has a severe and irreversible abnormality’,
deﬁned as ‘a life threatening physical condition that… regardless of
the provision of life saving medical treatment, is incompatible with
life outside the womb’ [93]. Similarly, the Columbian Penal Code
permits termination “when there are serious malformations of the
fetus that make the fetus not viable, as certiﬁed by amedical doctor’[94]. The terms ‘not viable’ and ‘incompatible with life’ appear to
relate to LM, and might have been intended to refer to conditions
listed in Box 1. Yet, the analysis indicates that anencephaly and even
bilateral renal agenesis are potentially compatible with long-term
survival and are ‘viable’ on strict deﬁnitions. If so, women car-
rying fetuses with LM may be unable to access termination.
It is beyond the scope of this paper to provide a detailed dis-
cussion of the legal or ethical approach to abortion law. Never-
theless, it is not our intention to limit women's options. For
jurisdictions that regard LM as a special case and wish to allow
abortion in such cases, there are perhaps three possibilities. One
possibility would be for lawmakers to create speciﬁc exceptions for
conditions such as those listed above. For example, the Brazilian
Supreme Court ruled that termination is permissible after diagnosis
of anencephaly (though not in other situations) [95]. Other condi-
tions could be added to this list, although in practice there may be
signiﬁcant hurdles in achieving such a law change. A second pos-
sibility would be to leave it to medical professionals to decide
which conditions are sufﬁciently severe to be regarded in law as
‘lethal’ or non-viable. The Columbian constitutional court has ruled
that ‘determinations are to be made bymedical practitioners acting
within the ethical standards of their profession’ [94]. However, the
lack of medical consensus about which conditions can and should
be considered ‘lethal’ would potentially lead to inconsistent de-
terminations and decision-making [85,96]. A third possibility
would be to draft legislation that sets out the speciﬁc ethical pre-
conditions for permitting termination of pregnancy. For example,
Chervenak and McCullough have argued that termination of
pregnancy should be permitted in the third trimester for conditions
with a high degree of certainty of diagnosis, and ‘a very high
probability of either death or survival with severe and irreversible
deﬁcit of cognitive developmental capacity’ [7,14]. This would
appear to include all of the conditions in Box 1.6. Conclusions
In this review, we have analysed and criticized the concept of
‘lethal’ congenital malformations. The term is misleading, and
potentially leads to miscommunication with families and incon-
sistent decision-making. None of the malformations frequently
described as ‘lethal’ ﬁts with strict deﬁnitions of this term. How-
ever, even if they are not lethal, the severity of conditions such as
anencephaly, renal agenesis, and T13/T18 means that perinatal
palliative care, maternal-focused obstetric care, and potentially
termination of pregnancy are justiﬁed. It may also be appropriate to
provide fetal-oriented obstetric care and some life-sustaining
treatments for these conditions where this is consistent with a
woman's wishes and the child's best interests.
Research directions
 Research is needed on parental response to language and
counseling approaches following diagnosis of severe
congenital malformations.
 There are few data on how frequently parents would
choose active or palliative approaches to care following
diagnosis of severe congenital malformations.
 There is a need to evaluate the impact of antenatal and
postnatal decisions on parents' long-term well-being.
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